NCT07077083

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment? Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.

Conditions

• Clear Cell Renal Cell Carcinoma (ccRCC)
• ccRCC

Interventions

Type	Name	Description
DRUG	89Zr-Girentuximab	89Zr-Girentuximab PET

Timeline

• Start date: 2026-03-16
• Primary completion: 2027-08-01
• Completion: 2028-08-01
• First posted: 2025-07-22
• Last updated: 2026-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study